CCNL2 and neoplasm: It has been well-defined that tumour-associated cell cycle defects are often mediated by the accumulation of cyclins (CCNs) and cyclin-dependent kinases (CDKs) complexes and reduced activity of cyclin-dependent kinase inhibitors (CDKIs) [23, 24].